Eikonizo Therapeutics

Eikonizo Therapeutics

Biotechnology, 700 Main St, Cambridge, Massachusetts, 02140, United States, 1-10 Employees

eikonizo.com

  • twitter
  • LinkedIn

phone no Phone Number: 19*********

Who is EIKONIZO THERAPEUTICS

Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeut...

Read More

map
  • 700 Main St, Cambridge, Massachusetts, 02140, United States Headquarters: 700 Main St, Cambridge, Massachusetts, 02140, United States
  • 2017 Date Founded: 2017
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 5122 | NAICS Code: 54 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from EIKONIZO THERAPEUTICS

Eikonizo Therapeutics Org Chart and Mapping

Employees

Clinton Bourbonais

Executive Director, Corporate Strategy and Operations

Tonya Gilbert

Executive Director of Translational Research

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Eikonizo Therapeutics

Answer: Eikonizo Therapeutics's headquarters are located at 700 Main St, Cambridge, Massachusetts, 02140, United States

Answer: Eikonizo Therapeutics's phone number is 19*********

Answer: Eikonizo Therapeutics's official website is https://eikonizo.com

Answer: Eikonizo Therapeutics's revenue is $1 Million to $5 Million

Answer: Eikonizo Therapeutics's SIC: 5122

Answer: Eikonizo Therapeutics's NAICS: 54

Answer: Eikonizo Therapeutics has 1-10 employees

Answer: Eikonizo Therapeutics is in Biotechnology

Answer: Eikonizo Therapeutics contact info: Phone number: 19********* Website: https://eikonizo.com

Answer: Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics. Our first program is focused on a disease-modifying therapeutic for neurodegenerative diseases.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access